IP Library Granted Patent US 7,867,511
Granted Patent B2
US 7,867,511 · App. 10/763,628 · Granted Jan 11, 2011

Abuse potential reduction in abusable substance dosage form

Assignee: Travanti Pharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,867,511
App. No.
10/763,628
Granted
Jan 11, 2011
Kind
B2
Abstract

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Claims (16)

1. A disposal system for a skin-worn transdermal patch device containing residual amount of an abusable opioid substance after use thereof on a patient, said system comprising:

(a) a disposal container separate from and independent of said skin-worn patch device and having an opening therein for receiving said skin-worn patch device;

(b) a deactivation system in said container comprising material that deactivates and renders unusable said abusable opioid substance on contact, comprising:

(1) a first amount of carbon in an activated state in a quantity sufficient to bind said abusable opioid substance in said patch;

(2) a second amount of carbon that has been pre-incorporated with a species that is releasable from said second amount of carbon upon solvent extraction and wherein said species is selected from the group consisting of capsaicin, ipecac, naloxone and naltrexone and combinations thereof such that said species remains with said abusable opioid substance upon extraction thereby rendering said abusable opioid substance unusable; and

(c) closure device for closing said disposal container thereby capturing said skin-worn patch device.

2. A system as in claim 1 wherein said container is in the form of a flexible pouch.

3. A system as in claim 1 wherein said closure device includes an adhesive seal.

4. A system as in claim 2 wherein said closure device includes an adhesive seal.

5. A system as in claim 1 wherein said opioid abusable substance comprises fentanyl.

6. A disposal system as in claim 1 wherein extraction solvents are water, ethanol and combinations thereof.

7. A disposal system as in claim 1 wherein said species includes capsaicin.

8. A disposal pouch for the deactivation of a used opioid transdermal patch comprising a deactivation system in said container comprising material that deactivates and renders unusable said abusable opioid substance on contact, comprising:

(a) a first amount of carbon in an activated state in a quantity sufficient to bind said abusable opioid substance in said patch;

(b) a second amount of carbon that has been pre-incorporated with a species that is releasable from said second amount of carbon upon solvent extraction and wherein said species is selected from the group consisting of capsaicin, ipecac, naloxone and naltrexone and combinations thereof such that said species remains with said abusable opioid substance upon extraction thereby rendering said abusable opioid substance unusable; and

(c) a container in the form of a pouch.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: TEIKOKU PHARMA USA, INC.
To: VERDE ENVIRONMENTAL TECHNOLOGIES, INC.
Reel/Frame 039563/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2011
From: TRAVANTI PHARMA INC.
To: TEIKOKU PHARMA USA, INC.
Reel/Frame 026435/0494 →
CHANGE OF NAME Recorded Dec 2, 2010
From: BIRCH POINT MEDICAL, INC.
To: TRAVANTI PHARMA INC.
Reel/Frame 025382/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2004
From: ANDERSON, CARTER R.; MORRIS, RUSSELL L.
To: BIRCH POINT MEDICAL INC.
Reel/Frame 014929/0799 →
Continuity (1)
Related Publication 20050163717A1 · Jul 28, 2005